At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Lundbeck Research USA
- Class Antidepressants; Anxiolytics; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
- Mechanism of Action 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 19 Jan 2000 Preclinical development for Depression in USA (Unknown route)
- 19 Jan 2000 Preclinical development for Smoking withdrawal in USA (Unknown route)
- 19 Jan 2000 Preclinical development for Substance-related disorders in USA (Unknown route)